Help your client overcome the challenges of patient recruitment, study design and market access with patient-centric solutions for rare disease and orphan drug development – find new approaches in this issue of Consultant Connection. |
CONSULTANT CONNECTION – OVERCOMING THE UNIQUE CHALLENGES FOR RARE DISEASE AND ORPHAN DRUG DEVELOPMENT |
Give your client insightful solutions to accelerate their orphan drug development program |
The development of orphan drugs to target rare diseases is growing due to recent financial and regulatory incentives. But even with these positive changes, developing treatments for rare disease presents many unique challenges beyond the scope of standard drug development. Here are some of the issues that your client may face:
|
Case Study: Assessing Study Feasibility with LabCorp Data A small virtual biotechnology company based in the US needed to launch a clinical program for a new treatment for cold agglutinin disease (CAD), a difficult-to-diagnose, rare autoimmune hematologic condition found only in about 1 in 300,000 people in the U.S. To extend their limited resources, the client needed comprehensive support on issues ranging from site selection to regulatory submissions. They requested a feasibility survey from Covance, who used LabCorp data to confirm the prevalence of the disease and identify potential sites for their clinical trials. |
Contact Your Consultant Connectors Lecia Johnson and her team are standing by to provide consultants with seamless access to Covance global solutions – preclinical through clinical, to registration and market access. Contact us today – we look forward to helping you succeed. Contact the team > |
From early development to post-market studies, you can apply our experience gained from supporting 56 indications across 103 studies in the last six years. Together, let’s help your client overcome key development challenges and make a lasting impact on unmet medical needs. |
Rare & Orphan Disease Resources |
More Consultant Connection Articles More innovative ways to advance your client's programs: |